200 related articles for article (PubMed ID: 37664059)
1. Non-canonical functions of EZH2 in cancer.
Zimmerman SM; Lin PN; Souroullas GP
Front Oncol; 2023; 13():1233953. PubMed ID: 37664059
[TBL] [Abstract][Full Text] [Related]
2. Regulation and Role of EZH2 in Cancer.
Yamaguchi H; Hung MC
Cancer Res Treat; 2014 Jul; 46(3):209-22. PubMed ID: 25038756
[TBL] [Abstract][Full Text] [Related]
3. Going beyond Polycomb: EZH2 functions in prostate cancer.
Park SH; Fong KW; Mong E; Martin MC; Schiltz GE; Yu J
Oncogene; 2021 Sep; 40(39):5788-5798. PubMed ID: 34349243
[TBL] [Abstract][Full Text] [Related]
4. The noncanonical role of EZH2 in cancer.
Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
[TBL] [Abstract][Full Text] [Related]
5. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
[TBL] [Abstract][Full Text] [Related]
6. Canonical and non-canonical roles of the histone methyltransferase EZH2 in mammary development and cancer.
Bae WK; Hennighausen L
Mol Cell Endocrinol; 2014 Jan; 382(1):593-597. PubMed ID: 23684884
[TBL] [Abstract][Full Text] [Related]
7. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
Mu W; Starmer J; Yee D; Magnuson T
Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
[TBL] [Abstract][Full Text] [Related]
8. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of EZH2 by CDK1 and CDK2: a possible regulatory mechanism of transmission of the H3K27me3 epigenetic mark through cell divisions.
Zeng X; Chen S; Huang H
Cell Cycle; 2011 Feb; 10(4):579-83. PubMed ID: 21278485
[TBL] [Abstract][Full Text] [Related]
10. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
[TBL] [Abstract][Full Text] [Related]
11. Exploring the therapeutic potential of targeting polycomb repressive complex 2 in lung cancer.
Gao M; Li Y; Cao P; Liu H; Chen J; Kang S
Front Oncol; 2023; 13():1216289. PubMed ID: 37909018
[TBL] [Abstract][Full Text] [Related]
12. Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations.
Wu H; Zeng H; Dong A; Li F; He H; Senisterra G; Seitova A; Duan S; Brown PJ; Vedadi M; Arrowsmith CH; Schapira M
PLoS One; 2013; 8(12):e83737. PubMed ID: 24367611
[TBL] [Abstract][Full Text] [Related]
13. EZH2: an emerging role in melanoma biology and strategies for targeted therapy.
Tiffen J; Gallagher SJ; Hersey P
Pigment Cell Melanoma Res; 2015 Jan; 28(1):21-30. PubMed ID: 24912396
[TBL] [Abstract][Full Text] [Related]
14. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
15. Role of EZH2 in Epithelial Ovarian Cancer: From Biological Insights to Therapeutic Target.
Li H; Zhang R
Front Oncol; 2013; 3():47. PubMed ID: 23494175
[TBL] [Abstract][Full Text] [Related]
16. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency.
Shen X; Liu Y; Hsu YJ; Fujiwara Y; Kim J; Mao X; Yuan GC; Orkin SH
Mol Cell; 2008 Nov; 32(4):491-502. PubMed ID: 19026780
[TBL] [Abstract][Full Text] [Related]
17. Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast Cancer.
Lawrence CL; Baldwin AS
PLoS One; 2016; 11(10):e0165005. PubMed ID: 27764181
[TBL] [Abstract][Full Text] [Related]
18. Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity.
Alzrigat M; Jernberg-Wiklund H; Licht JD
Epigenomes; 2018 Sep; 2(3):. PubMed ID: 30761216
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the positive transcriptional effect of PLZF through a non-canonical EZH2 activity.
Koubi M; Poplineau M; Vernerey J; N'Guyen L; Tiberi G; Garciaz S; El-Kaoutari A; Maqbool MA; Andrau JC; Guillouf C; Saurin AJ; Duprez E
Nucleic Acids Res; 2018 Apr; 46(7):3339-3350. PubMed ID: 29425303
[TBL] [Abstract][Full Text] [Related]
20. Regulation of T Cell Differentiation and Function by EZH2.
Karantanos T; Chistofides A; Barhdan K; Li L; Boussiotis VA
Front Immunol; 2016; 7():172. PubMed ID: 27199994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
